Atom Investors LP Invests $49,000 in OraSure Technologies, Inc. (NASDAQ:OSUR)

Atom Investors LP acquired a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,507 shares of the medical instruments supplier’s stock, valued at approximately $49,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Walleye Capital LLC acquired a new position in OraSure Technologies in the third quarter valued at approximately $835,000. Martingale Asset Management L P boosted its position in OraSure Technologies by 8.2% during the 3rd quarter. Martingale Asset Management L P now owns 262,873 shares of the medical instruments supplier’s stock valued at $1,122,000 after purchasing an additional 19,926 shares during the period. BNP Paribas Financial Markets grew its stake in OraSure Technologies by 27.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock worth $3,655,000 after buying an additional 183,191 shares during the last quarter. Intech Investment Management LLC bought a new position in OraSure Technologies during the 3rd quarter worth $84,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in OraSure Technologies by 78.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 12,604 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 4th.

OraSure Technologies Price Performance

Shares of OSUR stock opened at $3.84 on Friday. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The firm has a market capitalization of $286.43 million, a price-to-earnings ratio of 25.60 and a beta of 0.03. The business has a 50 day simple moving average of $4.05 and a 200 day simple moving average of $4.27.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company had revenue of $39.92 million during the quarter, compared to analysts’ expectations of $38.97 million. During the same quarter in the prior year, the business posted $0.27 earnings per share. The company’s revenue for the quarter was down 55.2% compared to the same quarter last year. On average, equities analysts anticipate that OraSure Technologies, Inc. will post -0.09 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.